πŸ‡ΊπŸ‡Έ FDA
Patent

US 9845512

Screening assay employing Dex and GDF8

granted A61KA61K31/573A61K38/1841

Quick answer

US patent 9845512 (Screening assay employing Dex and GDF8) held by Rigel Pharmaceuticals, Inc. expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Dec 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/573, A61K38/1841, A61K45/06, A61P